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OBJECTIVES: Expert consensus recommends calendar based in-office follow-up
(FU) for pacemakers (PM) twice annually, for internal cardioverter defibrillator (ICD)
or cardiac resynchronisation therapy devices (CRT) four times a year. To estimate
the societal costs of these FUs in Germany and the UK (UK). To estimate potential
cost savings from switching from conventional to a BIOTRONIK Home Monitoring
FU (remote monitoring) regimen. METHODS: Prevalence-based estimates on the
number of in-office FU visits were combined with data on private and ambulance
transport and hospital services, with costs projected until 2015. RESULTS: Annual
cost of routine FU in Germany are estimated to climb from EURO 106 mio (2010) to
142 mio (2015). For the UK, costs are forecast to rapidly increase from EURO 31 mio
(2010) to 49 mio (2015). In Germany, patients bear the majority of the costs (61%),
followed by hospital service costs (31%). In the UK, the situation is reversed with
hospital costs contributing the most (84%), followed by patient travel costs (12%).
The remainder is health insurance costs for ambulance transport. If 50% of all
patients would attend one in-office visit annually and have their other FUs per-
formed with Home Monitoring, annual cost savings in 2015 could reach EURO 43.9
mio in Germany, and EURO 14.7 mio in the UK. CONCLUSIONS: For the first time,
costs of FU for PM and ICD/CRT in Germany and the UK are presented. As modern
devices are capable to self-declare parameter deviations indicative for malfunc-
tions or worsening disease, remote monitoring can help eliminating unnecessary
visits. The presented savings are expected to be heavily underestimated due to not
considering the impact of earlier event detection and improved disease outcomes.
Savings could be invested in remote monitoring technologies, and freed medical
specialist capacities be re-directed to CIED patients in real need of FU visits.
PMD16
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OBJECTIVES: In the US the monitoring of patients with Chronic Myeloid Leukaemia
(CML) presents extensive intra- and inter-lab variability, thus a standardised, au-
tomated test should allow for improvement in patient management and health
outcomes. The aim of the study was to estimate the budget impact and improved
testing accuracy associated with a the use of a standardised, automated BCR-ABL
monitoring test (SBAT) when compared to laboratory developed tests (LDTs) for
newly diagnosed CML patients over a 5-year period in the US.METHODS: Epidemi-
ology data regarding the incidence of Philadelphia positive (Ph) CML patients who
would be treated with a tyrosine kinase inhibitor (TKI) were combined with work-
flow cost and accuracy (sensitivity and specificity) data associated with the se-
quential testing and monitoring of newly diagnosed CML patients. A survey of US
laboratories was conducted to determine the labour and materials costs associated
with the SBAT versus LDTs. A testing algorithm based on NCCN guidelines was
used to capture a number of different tests including testing for major molecular
response (SBAT versus LDTs), complete cytogenetic response (routine and FISH-
fluorescence in situ hybridisation), and mutation analysis. RESULTS: Results indi-
cate that the SBAT is both less resource- and labour- intensive, and can be carried
out at a cost that is lower than when an LDT is used. In addition, overall test
accuracy increases when the SBAT is used instead of an LDT. For example, for every
100 patients who follow BCR-ABL monitoring according to NCCN guidelines, sav-
ings of approximately $386,180 and approximately 327 more accurate test results
could be achieved over 5 years. CONCLUSIONS: The benefits from a SBAT when
compared to LDTs are not only from the reduction of intra- and inter-lab variability
(increased accuracy) but also in economic terms due to lower overall costs. There-
fore, a SBAT represents a cost-saving alternative versus LDTs.
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OBJECTIVES: The aim of this paper is to illustrate a methodology to develop a BIA,
assisting the decision maker in answering the question on financial sustainability.
METHODS:The analysis compared the new coated urethral catheter (alternative A)
to the long-term catheter currently in use in the region (alternative B). The study,
built on efficacy data including “asymptomatic bacteriuria” solely, adopted the
perspective of the Regional Health Service. A survey was conducted in seven local
health authorities (LHAs) within the Region to obtain consumption data and the
average price of respectively the new and currently used long-term catheters. The
estimate of regional consumption of alternative B was obtained by projecting the
consumption of 7 LHAs on the basis of the percentage of total inpatient admissions.
The analysis included technology costs and the costs of additional hospitalization
days due to Catheter Associated Urinary Tract Infections (CAUTI). Sensitivity anal-
yses were conducted to test the robustness of the results in the “base case”.
RESULTS: In 2010 approximately 25.000 long-term catheters with an average price
of 3.57 € were consumed. The regional estimate of annual consumption is about
221.560 catheters, with a total cost of € 791.000 per year. In the case of adopting
alternative A, the base case analysis estimated savings of around € 200.000 per year.
The one-way sensitivity analysis confirmed the extreme variability of the final
result as a function of the confidence interval of the clinical efficacy. A more favor-
able result for the new catheter can be reached using a “two-way” analysis, com-
bining a higher CAUTI incidence and a higher level of effectiveness (€2.045.866).
CONCLUSIONS: The results are strongly influenced by the effectiveness of the new
technology: a slight clinical benefit is enough to make the new catheter economi-
cally viable.
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OBJECTIVES:Open spine surgery (OS) is associated with significant muscle trauma
leading to delayed recovery, prolonged pain, and significant medical resource uti-
lization. Minimal Access Spinal Technologies (MAST™) aim at minimizing muscle
trauma, reduce blood loss, decrease postoperative pain, reduce length of stay in
hospital (LoS), and expedite return to normal activities for the patient. The objec-
tive of this study is to determine and compare the resource consumption associ-
ated with open vs. minimal invasive surgery in patients with degenerative spinal
disorder. METHODS: This activity-based cost-analysis was conducted in two Ital-
ian hospitals where patient flow and resource utilization were mapped and seg-
mented through interviews with medical staff. Unit costs were retrieved from pub-
lic sources and hospital data for the following categories 1) staff time; 2) tests; 3)
drugs/consumables; 4) operating room (OR); 5) spinal implants/instrumentation;
and 6) general costs. Costs were compared between pathways (open vs. MAST™)
and for each phase (pre-hospitalization, hospitalization, surgery, post-surgery and
follow-up. RESULTS: Both surgery and post-surgery were the most resource in-
tense episodes: on average post-surgery accounted for 14% of the total costs in
MAST™, and 24% in OS. MAST™ was associated with less overall resource use in
both hospitals, mainly driven by shorter LoS post surgery (2 vs. 4 days), less blood
loss and less demanding wound care. Total hospitalization costs were €6970-8310
for MAST™ and €8021- 8760 for OS. CONCLUSIONS: The study confirms published
evidence on the shorter LoS with MAST™ and the economic benefits of a less
invasive procedure. Despite initial higher investments (instrumentation, learning
curve) MAST™ may be an effective and cost-saving alternative to OS. Further cost
savings may be incurred due to faster return to work, not investigated in this study.
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OBJECTIVES: About 190,000 Germans suffer a myocardial infarction (MI) each year.
Of these, 25% may be eligible for an implantable cardioverter defibrillator (ICD) due
to low left ventricular ejection fraction. Given the high costs of implantation, the
purpose of this study was to assess the cost-effectiveness of ICDs compared to
conventional therapy in patients with an ejection fraction  30% after MI in
Germany. METHODS: The economic evaluation was performed from the perspec-
tive of the German statutory health insurance (SHI). In order to simulate costs and
effectiveness over lifetime, a Markov model was constructed with 7 health states.
The model was based on 8-year follow-up data for ICD implantation after MI (MA-
DIT II), which were published recently. RESULTS: The analysis shows that ICD
implantation compared to conventional therapy in patients fulfilling MADIT-II cri-
teria has a cost-effectiveness ratio of €44 736 per quality-adjusted life year gained.
If every patient insured by the SHI and fulfilling the MADIT-II criteria would receive
an ICD, the model suggests expenditures between €173 million and €1.7 billion per
year.CONCLUSIONS: ICD therapy cannot be considered clearly cost-effective when
compared to many well-accepted interventions. If policy makers decide to reim-
burse ICDs in the MADIT-II population, they will need to either raise premiums or
abandon coverage for other currently funded medical interventions.
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OBJECTIVES: Deep brain stimulation (DBS) use in dystonia is associated with high
energy needs and as such frequent replacement of the device. The first recharge-
able DBS device (Activa
®
RC) offers a guaranteed 9 years longevity. Our objective is
to perform a cost analysis of Activa
®
RC compared to the non rechargeable neuro-
stimulators in dystonia patients in France. METHODS: A retrospective data collec-
tion was performed in a Neurosurgery Department (Pr. Ph. Coubes - Montpellier
Public Hospital) with significant experience in DBS for dystonia. The cost analysis
was based on direct medical costs, from a national insurance perspective. The
evaluation concerns the device and hospitalization tariffs, the procedure cost being
included in the hospitalization tariffs, in France, for the public hospitals. We com-
pared the time to replacement with non-rechargeable devices versus rechargeable
device, extrapolated over 9 years. A sensitivity analysis was performed using time-
to-replacement variable. RESULTS: The cohort included 63 consecutive dystonia
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patients, implanted with a non-rechargeable device (Kinetra™, Soletra™, Itrel
®
2)
between 1996 and 2010. Overall, 117 implantations were performed (primo-implan-
tation and replacement). The mediane time to replacement of the non-recharge-
able devices was 2.9 years, ranging between 0.4 and 7.8 years. When extrapolated to
the cohort population, the use of the rechargeable device would have avoided a
total number of 215 hospitalizations over 9 years. The number of days of hospital-
ization avoided per patient was 10 days. The direct medical cost (device and hos-
pitalization tariffs) avoided per patient was 27 886€. CONCLUSIONS: Over 9 years,
the rechargeable DBS device allows to avoid 2 device replacements per patient.
This is associated with a 40 % reduction of the total number of days in hospital, and
43% reduction in the direct medical cost. The rechargeable neurostimulator
Activa
®
RC is adapted to patients with high energy needs like dystonia patients,
with a time to replacement of 5 years or less.
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OBJECTIVES: PRECISE study aims to assess the costs and the clinical benefits of
Spinal Cord Stimulation (SCS) (plus conventional medical management, CMM) in
the treatment of Failed Back Surgery Syndrome (FBSS) patients not adequately
responding to CMM alone. Being the study closed, we report the preliminary clin-
ical and resource consumption final results.METHODS:An observational, pre-post
data collection with a 24-months follow-up (FU) was developed in 9 Italian Hospi-
tals. Resource consumption, clinical outcomes (Pain Numerical Rating Scale - NRS,
Oswestry Disability Index - ODI) and HR-QoL data (SF-36, EQ-5D) were collected
before and after the SCS system implantation in order to be compared. RESULTS:
Fifty-five of the 72 patients implanted (out of the 80 enrolled for the SCS screening)
completed the study. Seventeen discontinued the therapy due to: consent with-
drawal (24%), loss to FU (24%), SCS-related issues (29%), non-SCS related reasons
(24%). Mean pain intensity decreased from 7.41.4 to 4.22.6 in the first 12 months,
remaining consistent through the second year of FU (4.12.5). A continuous im-
provement in function measured with ODI was appreciated: 47 (85%) patients im-
proved in the first year and 33 (60%) during the second, for a total of 41 (82%)
patients improved at 24-month FU if compared to the baseline. EQ-VAS increased
from 37 to 60 (12-months) to 63 (24-months). All SF-36 domains significantly im-
proved, and especially “Bodily Pain”, “Social Functioning”, “Role Emotional”. With
respect to the baseline, the monthly per-patient resource consumption decreased:
considering the second year of follow-up, both pain-related hospitalizations and
GP visits experienced a 70% reduction in number, diagnostic exams diminished by
the 82%. Monthly caregivers’ days off from work dropped by the 80% (from 45 to 9).
CONCLUSIONS: SCS allows a better and sustained pain control and HR-QoL im-
provement. If compared with CMM alone, SCS permits a reduction in resource
consumption and productivity losses.
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OBJECTIVES:Diagnosis of patients with dyspnea and suspected acute heart failure
(HF) using NT-proBNP testing has been studied internationally. We aimed to ana-
lyze the efficiency of NT-proBNP compared to standard clinical evaluation alone
use in Spanish Emergency Departments. METHODS: A decision-analytic model
was developed to evaluate the clinical and economic outcomes of both diagnostic
alternatives. Model’s time horizon started at patient ED visits and ended after 60
days of follow-up (taking into account differences between hospitalized and non-
hospitalized patients). Clinical parameters were mainly extracted from the PRIDE
study and were validated by expert opinion (ED and cardiology doctors). We as-
sumed that 65% of patients with dyspnea had HF based on Spanish published data.
Resource use was obtained through expert opinion and examined under a National
Healthcare System (NHS) perspective. We considered a 900 pg/ml cut-point for
NT-proBNP test (sensitivity of 90% and specificity of 85%). Our model compared
final diagnostic result with the initial diagnostic before ED discharge. A probabilis-
tic sensitivity analysis was carried out in order to handle uncertainty. RESULTS:
Diagnosis using NT-proBNP testing was correct in 91.96% of patients (59.09% true
positive cases and 32.87% true negative cases) versus 85.53% with the standard
clinical evaluation alone (50.79% of true positive cases and 34.74% of true negative
cases). Besides, NT-proBNP testing involved less costs (4,045€ versus 5,405€) mainly
due to less hospitalizations and a shorter length of stay. Robustness of results was
confirmed through a sensitivity analysis. CONCLUSIONS: NT-proBNP test is less
costly per correctly diagnosed patient than standard clinical evaluation alone in
the assessment and management of patients with dyspnea at ED rooms from Span-
ish NHS perspective.
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OBJECTIVES: Liver imaging techniques aim to correctly characterize focal lesions
and influence choices of therapeutic strategies. The objective of this study was to
compare diagnostic efficacy and direct medical costs of contrast-enhanced ultra-
sound (CEUS) to magnetic resonance imaging (MRI) or computed tomography (CT)
in the characterization of focal liver lesions in the The Netherlands. METHODS:
This prospective study enrolled 170 patients at an academic hospital in the The
Netherlands. A decision model was designed to compare two diagnostic algorithms
based on the results of the study: 1) a typical patient work-up, which included
ultrasound (US), followed by an MRI or CT examination, and 2) a new patient
work-up in which CEUS was performed after US. The perspective of the healthcare
sector in the The Netherlands was used. Clinical outcomes were ‘correctly charac-
terizedx benign and malignant liver lesions and life-years (LY). Model inputs were
taken from the hospital database, literature and publicly available sources. Time
horizon was two years. One-way and probabilistic sensitivity analyses were per-
formed to assess uncertainty in the results. RESULTS: CEUS was able to identify
benign and malignant focal liver lesions with a sensitivity of 96.9% and specificity
of 92.3%. For correct tumor subgroup characterization, sensitivity and specificity
were 86.2% and 85.6% respectively. Base-case results revealed that the CEUS strat-
egy had similar effectiveness compared to the MRI/CT strategy (incremental effects
of 0.002 LYs) and resulted in cost-savings of €452. The cost-savings for diagnostic
phase and treatment phase were €160 and €292 respectively. The results were
sensitive to specificity, sensitivity and cost of the diagnostic tests. Robustness of
the results was confirmed by probabilistic sensitivity analysis. CONCLUSIONS:
This study demonstrates that CEUS is a cost-saving alternative compared to the
traditional diagnostic procedures and should be considered as one of the ‘first
stepx options in the front-line characterization of focal liver lesions in the The
Netherlands.
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OBJECTIVES: The treatment of chronic lymphoedema (CL) is of particular health
economic interest since, due to its chronic nature and continuous need for treat-
ment, it is associated with high costs and considerable patient burden. The objec-
tive of this study was to assess the cost-effectiveness of 3M™ Coban 2™ compres-
sion system in the treatment of CL compared to Comprilan® short-stretch bandage
compression therapy. METHODS: In the UK and the United States a multi-center,
prospective, open-label study was conducted, including patients with CL of the legs
(n40) and the arms (n42). Patients were randomly assigned to the four treatment
arms (3M™ Coban 2™ compression treatment either daily, 2x/wk or 3x/wk, and
daily compression therapy with Comprilan® bandages). Cost analysis from the UK
payors’ perspective was based on material costs and personal resource utilization
for bandage changes and for manual lymphtherapy. Clinical outcomes in the cost-
effectiveness analysis was defined as mean volume reduction at the end of therapy
(19 days). RESULTS: On average, 3 weeks treatment for a patient with lymphoe-
dema added to 1,297.96 € for the health service comissioners and up to 576,54 € for
the physiotherapists across all groups. Lymphoedema treatment with 3M™ Coban
2™ compression system twice a week was more cost-effective than the other treat-
ments (ICER 37.65 € per % reduction of circumference vs. 146.60 € (daily), 145.67 €
(3x/wk) and 147.53 € (daily compression therapy with Comprilan® bandages)). Re-
sults were comparable for patients with CL of the upper and lower extremities,
respecitvely. Sensitivity analysis provided stable results after variation of costs,
utilization rates and clinical outcomes. CONCLUSIONS: Treatment of lymphoe-
dema with 3M™ Coban 2™ compression system twice a week is more efficient than
treatments applied daily or three times per week.
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OBJECTIVES: Transcatheter aortic valve implantation (TAVI) represents an inno-
vative technology superior to medical management (PARTNER study, US) in inop-
erable patients with severe aortic valve stenosis (AVS). This study aims to estimate
the cost-effectiveness of TAVI compared to conservative medical management in
symptomatic AVS patients in Spain. METHODS: A economic longitudinal cohort
model was used to predict clinical and economic outcomes of symptomatic AVS
patients treated with either transapical (TA) or transfemoral (TF) TAVI, or medical
management alone (MEDICAL). Clinical model input data for TAVI was derived
from the real-world SOURCE registry, and for MEDICAL from literature and a reg-
istry of 60 untreated Spanish AVS patients followed up for 336 days. Health utilities
as well as resource use and unit costs utilized for modelling are representative for
Spain. Missing information was substituted by expert estimates. Economic results
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